TY - JOUR
T1 - CVOT Summit Report 2023
T2 - new cardiovascular, kidney, and metabolic outcomes
AU - Schnell, Oliver
AU - Barnard-Kelly, Katharine
AU - Battelino, Tadej
AU - Ceriello, Antonio
AU - Larsson, Helena Elding
AU - Fernández-Fernández, Beatriz
AU - Forst, Thomas
AU - Frias, Juan Pablo
AU - Gavin, James R.
AU - Giorgino, Francesco
AU - Groop, Per Henrik
AU - Heerspink, Hiddo J.L.
AU - Herzig, Stephan
AU - Hummel, Michael
AU - Huntley, George
AU - Ibrahim, Mahmoud
AU - Itzhak, Baruch
AU - Jacob, Stephan
AU - Ji, Linong
AU - Kosiborod, Mikhail
AU - Lalic, Nebosja
AU - Macieira, Sofia
AU - Malik, Rayaz A.
AU - Mankovsky, Boris
AU - Marx, Nikolaus
AU - Mathieu, Chantal
AU - Müller, Timo D.
AU - Ray, Kausik
AU - Rodbard, Helena W.
AU - Rossing, Peter
AU - Rydén, Lars
AU - Schumm-Draeger, Petra Maria
AU - Schwarz, Peter
AU - Škrha, Jan
AU - Snoek, Frank
AU - Tacke, Frank
AU - Taylor, Bruce
AU - Jeppesen, Britta Tendal
AU - Tesfaye, Solomon
AU - Topsever, Pinar
AU - Vilsbøll, Tina
AU - Yu, Xuefeng
AU - Standl, Eberhard
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).
AB - The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).
KW - CGM
KW - Cardiovascular disease
KW - Chronic kidney disease
KW - Diabetes
KW - Finerenone
KW - GLP-1 RA
KW - Guidelines
KW - Heart failure
KW - MASLD
KW - NAFLD
KW - Obesity
KW - SGLT2 inhibitor
KW - Teplizumab
UR - https://www.scopus.com/pages/publications/85188142815
U2 - 10.1186/s12933-024-02180-8
DO - 10.1186/s12933-024-02180-8
M3 - Comment/debate
C2 - 38504284
AN - SCOPUS:85188142815
SN - 1475-2840
VL - 23
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 104
ER -
SDG 3 Good Health and Well-being